3-氯吡啶-4-羧胺 | 100859-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氯吡啶-4-羧胺
• 中文别名: 3-氯异烟酰胺
• 英文名称: 3-chloro-isonicotinic acid amide
• 英文别名: 3-Chlor-isonicotinsaeure-amid；3-Chloropyridine-4-carboxamide
• CAS: 100859-32-3
• 化学式: C₆H₅ClN₂O
• mdl: MFCD09907954
• 分子量: 156.572
• InChiKey: PPLLAHQNNDKXJU-UHFFFAOYSA-N

物化性质

• 沸点：
  295.5±25.0 °C(Predicted)
• 密度：
  1.381±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  3-羟基异烟酸 在 三氯氧磷 作用下， 生成 3-氯吡啶-4-羧胺
  参考文献：
  名称：

  Nuclear Substitution Derivatives of Isonicotinic Acid

  摘要：

  DOI：

  10.1021/jo01095a019

文献信息

• SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：CZECHTIZKY Werngard

  公开号：US20130065859A1

  公开（公告）日：2013-03-14

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色甘醇-6-氧基)-噻唑衍生物，其中Ar、R2、R3和R4如权利要求中所定义。式I的化合物是钠-钙交换蛋白（NCX）的抑制剂，特别是亚型1的钠-钙交换蛋白（NCX1），适用于处理细胞内钙离子稳态受扰的各种疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• Triphenylphosphine derivative, production process therefor, palladium complex thereof, and process for producing biaryl derivative
  申请人：——

  公开号：US20030065208A1

  公开（公告）日：2003-04-03

  Provided are a novel triphenyl phosphine derivative synthesized from a triphenylphosphine and a hydroxy-containing lactone; a palladium and a nickel complexes comprising the derivative as a ligand; and a process for preparing a biaryl derivative using the complex as a catalyst. A product can be easily separated from a catalyst or a phosphorus compound, and biaryl derivative can be synthesized in a higher yield, by using the complex of the present invention as a catalyst.

  提供了一种新型的三苯基膦衍生物，通过三苯基膦和含羟基的内酯合成；一种以该衍生物为配体的钯和镍配合物；以及一种利用该配合物作为催化剂制备联苯衍生物的方法。通过使用本发明的复合物作为催化剂，产品可以很容易地与催化剂或磷化合物分离，联苯衍生物可以以更高的产率合成。
• PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B.

  公开号：US20130190309A1

  公开（公告）日：2013-07-25

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的调节sirtuin的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞的寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症、潮红以及那些会受益于增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物与另一种治疗剂结合的组合物。
• [EN] PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS<br/>[FR] PHTALAZINONE ET ANALOGUES APPARENTÉS EN TANT QUE MODULATEURS DE LA SIRTUINE
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2010077947A1

  公开（公告）日：2010-07-08

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.

  本文提供了新颖的去乙酰化酶调节化合物及其使用方法。这些去乙酰化酶调节化合物可用于延长细胞的寿命，并用于治疗和/或预防各种疾病和紊乱，包括与老化或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症、潮红等相关的疾病或紊乱，以及那些可能受益于增加线粒体活性的疾病或紊乱。还提供了包含去乙酰化酶调节化合物与另一治疗剂组合的组合物。
• Benzofuropyrimidinones
  申请人：Brown S. David

  公开号：US20090247559A1

  公开（公告）日：2009-10-01

  A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3a , R 3b , R 3c and R 3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  公式I所示的化合物或其药学上可接受的盐；其中R1、R2、R3a、R3b、R3c和R3d如规范中所定义，以及其药物组合物和使用方法。